Qubit Pharmaceuticals

Executive Summary

Qubit Pharmaceuticals is a privately held, pre-clinical biotechnology company headquartered in Paris, France, founded in 2020. The company leverages cutting-edge quantum physics-based science and artificial intelligence to achieve unparalleled accuracy and precision in drug discovery and design, with a focus on small molecule therapeutics. By integrating quantum mechanics simulations and machine learning, Qubit aims to reduce the high failure rates in drug development by predicting molecular interactions with superior fidelity, thereby accelerating the identification of novel drug candidates. Their platform targets major diseases with significant unmet medical needs. Currently in the pre-clinical stage, the company has not disclosed specific pipeline programs or total funding raised, but its innovative approach positions it as a potential leader in the AI-driven drug discovery space.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a strategic partnership with a major pharmaceutical company for co-development of a lead program35% success
• Q4 2026Selection of a clinical candidate for the lead program and initiation of IND-enabling studies45% success
• Q2 2027Closing of a Series B financing round to support expansion of platform and pipeline55% success